Carmen Navarrete
Cordoba, AN, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Etrinabdione (VCE-004.8), a B55α activator, promotes angiogenesis and arteriogenesis in critical limb ischemia.
Journal: Journal of translational medicine
Published: June 04, 2024
Investigation in the cannabigerol derivative VCE-003.2 as a disease-modifying agent in a mouse model of experimental synucleinopathy.
Journal: Behavioral and brain functions : BBF
Published: May 20, 2024
VCE-005.1, an hypoxia mimetic betulinic acid derivative, induces angiogenesis and shows efficacy in a murine model of traumatic brain injury.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: February 06, 2023
A cannabidiol aminoquinone derivative activates the PP2A/B55α/HIF pathway and shows protective effects in a murine model of traumatic brain injury.
Journal: Journal of neuroinflammation
Published: March 07, 2022
Cannabidiol and Other Cannabinoids in Demyelinating Diseases.
Journal: International journal of molecular sciences
Published: February 27, 2021
EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: January 12, 2021
Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice.
Journal: Molecular and cellular neurosciences
Published: October 24, 2020
Cannabinoids in Metabolic Syndrome and Cardiac Fibrosis.
Journal: Current hypertension reports
Published: September 28, 2020
Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis.
Journal: Neurobiology of disease
Published: March 27, 2020
Structure-Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives.
Journal: Frontiers in pharmacology
Published: June 05, 2019
Cannabinoid derivatives acting as dual PPARγ/CB2 agonists as therapeutic agents for systemic sclerosis.
Journal: Biochemical pharmacology
Published: January 16, 2019
Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration.
Journal: Translational neurodegeneration
Published: November 22, 2018
Last Updated: 09/26/2026